The Stop TB Partnership releases the estimated country shares of global targets committed in the Political declaration of the UN High-Level Meeting on TB, held in September 2023.

A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The Improved Management with Antimicrobial Agents Isoniazid Rifampicin Linezolid for TBM (IMAGINE-TBM) trial will compare a six-month regimen of four drugs with the nine-month, standard-of-care regimen for TBM. The study aims to generate evidence that could improve treatment for people with TBM. IMAGINE-TBM is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and implemented through the NIAID-funded Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG).

TB research and development funding perilously off track of UN commitments to end TB by 2030.

The value, speed of completion and robustness of the evidence generated by TB treatment clinical trials could be improved by implementing standards for best practice.

A proportion of patients with drug-resistant tuberculosis (TB) receive ineffective treatment due to misdiagnosis by rapid molecular tests, according to a genomic analysis carried out in southern Mozambique and co-led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by "la Caixa" Foundation, and the Institute of Biomedicine in Valencia (IBV), from the Spanish National Research Council (CSIC). The results indicate that new molecular tests need to be developed to detect a wider range of mutations that confer resistance to first-line TB drugs.

1 December 2023 | Genev -- World AIDS Day 2023 this year focuses on unleashing the full potential of community leadership to enable the end of AIDS. People and communities affected by tuberculosis (TB) are critical stakeholders in ending both TB and HIV.

RESIST-TB will host a webinar on 7 December 2023 'Time for $5 Campaign - A call on Cepheid to drop the price of GeneXpert to $5'.

RESIST-TB released its December 2023 newsletter with the latest updates and research publications on drug-resistant TB.

A collaborative study between the A*STAR Infectious Diseases Labs (A*STAR ID Labs) and the University of Massachusetts (UMass) Chan Medical School has uncovered that elevated glycerol levels are responsible for increased severity of tuberculosis (TB) disease in experimental models with type 2 diabetes (T2D).

Each year, tuberculosis (TB) kills more people than any other infectious disease, falling out of the top spot only temporarily during the COVID-19 pandemic.